Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | BPTF | Q12830 | 1/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1286210 | 0.86 | TPMT (0.54) | ALDH1A1MEN1KMT2AKDM4EHSD17B2 | |
| SCHEMBL13446716 | 0.86 | LMNA (0.51) | ALDH1A1MEN1KMT2AKDM4EHSD17B2 | |
| SCHEMBL11279398 | 0.82 | TSHR (0.50) | ALDH1A1MEN1KMT2AKDM4EHSD17B2 | |
| SCHEMBL9621348 | 0.80 | BPTF (0.56) | ALDH1A1MEN1KMT2AKDM4EBPTF | |
| SCHEMBL28396192 | 0.79 | ALOX15 (0.48) | ALDH1A1MEN1KMT2AKDM4EHSD17B2 | |
| SCHEMBL668245 | 0.78 | TUBB4A (0.50) | ALDH1A1MEN1KMT2ATSHRHPGD | |
| SCHEMBL11337985 | 0.78 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2AKDM4EGABRA1 | |
| SCHEMBL11337980 | 0.78 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AKDM4EHSD17B2 | |
| SCHEMBL219096 | 0.77 | TUBB4A (0.55) | ALDH1A1MEN1KMT2AKDM4ETSHR | |
| SCHEMBL28275397 | 0.77 | TUBB4A (0.55) | ALDH1A1MEN1KMT2AKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691844-B2 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7365062-B2 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7238687-B2 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070135409-A1 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070117790-A1 | 4-(2-fluorophenylbenzoyl-4-aminobenzoyl)-3'-(2-(N,N-dimethylaminoethylaminocarbonyl))-4-aza-[6,4]-spiro-[5,6]-benzoundec-2'-ene; inner ear disorders, hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2007-05-24 | — | — | US | disclosed |
| US-20060111567-A1 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | CHEN ROBERT H | 2006-05-25 | — | — | US | disclosed |
| US-7001898-B2 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1307430-B1 | NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINES AS VASOPRESSIN ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20030045517-A1 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-03-06 | — | — | US | disclosed |
| EP-0541798-B1 | NEW DIAMINE COMPOUND AND BRAIN PROTECTING AGENT CONTAINING THE SAME | KOWA CO (JP) | 1995-11-29 | — | — | EP | disclosed |
| US-5389630-A | Diamine compound and brain protecting agent containing the same | KOWA CO., LTD. (JP) | 1995-02-14 | — | — | US | disclosed |
| EP-0541798-A1 | NEW DIAMINE COMPOUND AND BRAIN PROTECTING AGENT CONTAINING THE SAME | Kowa Company Ltd. (JP) | 1993-05-19 | — | — | EP | disclosed |
| US-4271193-A | PROPHYLAXIS AND TREATMENT OF GASTRITIS | KALI-CHEMIE PHARMA GMBH (DE) | 1981-06-02 | — | — | US | disclosed |
| EP-0006458-A1 | N1-Benzoyl-N2-phenyl-1,3-diaminopropane-2-ols and their salts, process for their preparation and medicaments containing them | Kali-Chemie Pharma GmbH (DE) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111567-A1 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | AVPR1B, AVPR2, AVPR1A | ALDH1A1 1346/4885MEN1 3255/4885KMT2A 3607/4885 |
| US-20070135409-A1 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | AVPR1B, AVPR2, AVPR1A | ALDH1A1 1346/4885MEN1 3255/4885KMT2A 3607/4885 |
| US-20030045517-A1 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | AVPR1B, AVPR2, AVPR1A | ALDH1A1 1027/4885MEN1 3410/4885KMT2A 3343/4885 |
| US-20070117790-A1 | 4-(2-fluorophenylbenzoyl-4-aminobenzoyl)-3'-(2-(N,N-dimethylaminoethylaminocarbonyl))-4-aza-[6,4]-spiro-[5,6]-benzoundec-2'-ene; inner ear disorders, hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure | AVPR1B, AVPR2, BDKRB1 | ALDH1A1 943/4885MEN1 2633/4885KMT2A 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.